unitedtherapeuticstyvaso

Personalize Your PH Treatment Approach. United Therapeutics is committed to continuously advancing the world of PH care. From offering effective treatments ...

2023年8月10日 — United Therapeutics UTHR reported robust second-quarter results highlighted by revenue of $597 million, representing growth of 28% year over ...

United Therapeutics has contracted with a limited distribution network of authorized specialty distributors and wholesalers. ASSIST works with Specialty ...

Learn more about Tyvaso® & Tyvaso DPI®, inhalation therapies developed by United Therapeutics for adults with PAH & PH-ILD.

Patient website for TYVASO® and TYVASO DPI®, inhaled treatments approved for the treatment of PAH and PH-ILD.

2022年5月24日 — United Therapeutics HQ An FDA approval for an inhaled version of Tyvaso could catapult United Therapeutics' PAH drug into blockbuster territory.

2022年5月24日 — SILVER SPRING, Md. ... Tyvaso DPI represents a new formulation and inhalation device for inhaled treprostinil and is the only dry powder inhaler ...

2022年5月25日 — Tyvaso DPI marks the first approval of a dry powder inhaler for the treatment of pulmonary arterial hypertension and pulmonary hypertension ...

Learn about United Therapeutics' commitment to helping patients with PAH and why support is an integral part of our treatments.